nodes	percent_of_prediction	percent_of_DWPC	metapath
Eprosartan—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.175	0.363	CbGbCtD
Eprosartan—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.175	0.363	CbGbCtD
Eprosartan—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.132	0.275	CbGbCtD
Eprosartan—Losartan—ACE—chronic obstructive pulmonary disease	0.00406	0.472	CrCbGaD
Eprosartan—AGTR1—ACE Inhibitor Pathway—ACE—chronic obstructive pulmonary disease	0.00362	0.0724	CbGpPWpGaD
Eprosartan—Losartan—CYP1A2—chronic obstructive pulmonary disease	0.00288	0.335	CrCbGaD
Eprosartan—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A2—chronic obstructive pulmonary disease	0.00179	0.0358	CbGpPWpGaD
Eprosartan—AGTR1—Arf6 signaling events—ADRB2—chronic obstructive pulmonary disease	0.00173	0.0347	CbGpPWpGaD
Eprosartan—AGTR1—ACE Inhibitor Pathway—NOS3—chronic obstructive pulmonary disease	0.00168	0.0337	CbGpPWpGaD
Eprosartan—Losartan—ALB—chronic obstructive pulmonary disease	0.00166	0.193	CrCbGaD
Eprosartan—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—chronic obstructive pulmonary disease	0.00166	0.0332	CbGpPWpGaD
Eprosartan—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A2—chronic obstructive pulmonary disease	0.00162	0.0325	CbGpPWpGaD
Eprosartan—AGTR1—Peptide GPCRs—CXCR2—chronic obstructive pulmonary disease	0.00152	0.0304	CbGpPWpGaD
Eprosartan—AGTR1—Arf6 trafficking events—ADRB2—chronic obstructive pulmonary disease	0.00137	0.0274	CbGpPWpGaD
Eprosartan—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—chronic obstructive pulmonary disease	0.0013	0.026	CbGpPWpGaD
Eprosartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.00128	0.0256	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—IL13—chronic obstructive pulmonary disease	0.00128	0.0256	CbGpPWpGaD
Eprosartan—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—chronic obstructive pulmonary disease	0.00118	0.0236	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—IL17A—chronic obstructive pulmonary disease	0.00118	0.0235	CbGpPWpGaD
Eprosartan—AGTR1—ACE Inhibitor Pathway—TGFB1—chronic obstructive pulmonary disease	0.00111	0.0223	CbGpPWpGaD
Eprosartan—CYP2C9—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000858	0.0172	CbGpPWpGaD
Eprosartan—CYP2C9—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000825	0.0165	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—IL10—chronic obstructive pulmonary disease	0.000799	0.016	CbGpPWpGaD
Eprosartan—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.000782	0.0017	CcSEcCtD
Eprosartan—Back pain—Salbutamol—chronic obstructive pulmonary disease	0.000782	0.0017	CcSEcCtD
Eprosartan—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.000777	0.00169	CcSEcCtD
Eprosartan—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	0.000777	0.00169	CcSEcCtD
Eprosartan—Malaise—Arformoterol—chronic obstructive pulmonary disease	0.000772	0.00168	CcSEcCtD
Eprosartan—Malaise—Formoterol—chronic obstructive pulmonary disease	0.000772	0.00168	CcSEcCtD
Eprosartan—Osteoarthritis—Prednisolone—chronic obstructive pulmonary disease	0.00077	0.00167	CcSEcCtD
Eprosartan—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.000766	0.00167	CcSEcCtD
Eprosartan—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000762	0.00166	CcSEcCtD
Eprosartan—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000757	0.00165	CcSEcCtD
Eprosartan—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.000756	0.00165	CcSEcCtD
Eprosartan—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.000756	0.00165	CcSEcCtD
Eprosartan—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.00075	0.00163	CcSEcCtD
Eprosartan—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	0.00075	0.00163	CcSEcCtD
Eprosartan—Cough—Formoterol—chronic obstructive pulmonary disease	0.000747	0.00162	CcSEcCtD
Eprosartan—Cough—Arformoterol—chronic obstructive pulmonary disease	0.000747	0.00162	CcSEcCtD
Eprosartan—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.000741	0.00161	CcSEcCtD
Eprosartan—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.00074	0.00161	CcSEcCtD
Eprosartan—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.000738	0.00161	CcSEcCtD
Eprosartan—Cough—Montelukast—chronic obstructive pulmonary disease	0.000731	0.00159	CcSEcCtD
Eprosartan—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000729	0.00159	CcSEcCtD
Eprosartan—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.000729	0.00159	CcSEcCtD
Eprosartan—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.000729	0.00158	CcSEcCtD
Eprosartan—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.000729	0.00158	CcSEcCtD
Eprosartan—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.000729	0.00158	CcSEcCtD
Eprosartan—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.000729	0.00158	CcSEcCtD
Eprosartan—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.000729	0.00158	CcSEcCtD
Eprosartan—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.000729	0.00158	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—SOD3—chronic obstructive pulmonary disease	0.000727	0.0146	CbGpPWpGaD
Eprosartan—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000726	0.00158	CcSEcCtD
Eprosartan—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000726	0.00158	CcSEcCtD
Eprosartan—Vertigo—Salbutamol—chronic obstructive pulmonary disease	0.000726	0.00158	CcSEcCtD
Eprosartan—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000725	0.00158	CcSEcCtD
Eprosartan—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000725	0.00158	CcSEcCtD
Eprosartan—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000725	0.00158	CcSEcCtD
Eprosartan—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.00072	0.00157	CcSEcCtD
Eprosartan—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.00072	0.00157	CcSEcCtD
Eprosartan—AGTR1—Peptide ligand-binding receptors—CXCR2—chronic obstructive pulmonary disease	0.000715	0.0143	CbGpPWpGaD
Eprosartan—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000714	0.00155	CcSEcCtD
Eprosartan—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000714	0.00155	CcSEcCtD
Eprosartan—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000714	0.00155	CcSEcCtD
Eprosartan—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000713	0.00155	CcSEcCtD
Eprosartan—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000713	0.00155	CcSEcCtD
Eprosartan—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000711	0.00155	CcSEcCtD
Eprosartan—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.00071	0.00154	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—NOS3—chronic obstructive pulmonary disease	0.00071	0.0142	CbGpPWpGaD
Eprosartan—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000708	0.00154	CcSEcCtD
Eprosartan—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000705	0.00153	CcSEcCtD
Eprosartan—Oesophagitis—Prednisone—chronic obstructive pulmonary disease	0.000704	0.00153	CcSEcCtD
Eprosartan—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000688	0.0015	CcSEcCtD
Eprosartan—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000688	0.0015	CcSEcCtD
Eprosartan—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000688	0.0015	CcSEcCtD
Eprosartan—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000688	0.0015	CcSEcCtD
Eprosartan—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000686	0.00149	CcSEcCtD
Eprosartan—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000684	0.00149	CcSEcCtD
Eprosartan—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000682	0.00148	CcSEcCtD
Eprosartan—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000682	0.00148	CcSEcCtD
Eprosartan—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.00068	0.00148	CcSEcCtD
Eprosartan—Muscular weakness—Prednisolone—chronic obstructive pulmonary disease	0.000679	0.00148	CcSEcCtD
Eprosartan—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000676	0.00147	CcSEcCtD
Eprosartan—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000673	0.00146	CcSEcCtD
Eprosartan—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.00067	0.00146	CcSEcCtD
Eprosartan—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000653	0.00142	CcSEcCtD
Eprosartan—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000653	0.00142	CcSEcCtD
Eprosartan—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000649	0.00141	CcSEcCtD
Eprosartan—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000649	0.00141	CcSEcCtD
Eprosartan—Sweating increased—Prednisolone—chronic obstructive pulmonary disease	0.000648	0.00141	CcSEcCtD
Eprosartan—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000644	0.0014	CcSEcCtD
Eprosartan—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	0.000643	0.0014	CcSEcCtD
Eprosartan—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000638	0.00139	CcSEcCtD
Eprosartan—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000638	0.00139	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000636	0.00138	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000636	0.00138	CcSEcCtD
Eprosartan—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000632	0.00137	CcSEcCtD
Eprosartan—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000632	0.00137	CcSEcCtD
Eprosartan—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000629	0.00137	CcSEcCtD
Eprosartan—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000628	0.00137	CcSEcCtD
Eprosartan—Vascular purpura—Prednisone—chronic obstructive pulmonary disease	0.000625	0.00136	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000623	0.00136	CcSEcCtD
Eprosartan—CYP2C9—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000623	0.0125	CbGpPWpGaD
Eprosartan—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000623	0.00135	CcSEcCtD
Eprosartan—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000623	0.00135	CcSEcCtD
Eprosartan—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000621	0.00135	CcSEcCtD
Eprosartan—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000621	0.00135	CcSEcCtD
Eprosartan—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000619	0.00135	CcSEcCtD
Eprosartan—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000616	0.00134	CcSEcCtD
Eprosartan—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000615	0.00134	CcSEcCtD
Eprosartan—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000615	0.00134	CcSEcCtD
Eprosartan—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000614	0.00134	CcSEcCtD
Eprosartan—AGTR1—Arf6 signaling events—EGFR—chronic obstructive pulmonary disease	0.000612	0.0123	CbGpPWpGaD
Eprosartan—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000612	0.00133	CcSEcCtD
Eprosartan—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000608	0.00132	CcSEcCtD
Eprosartan—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000607	0.00132	CcSEcCtD
Eprosartan—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000602	0.00131	CcSEcCtD
Eprosartan—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000602	0.00131	CcSEcCtD
Eprosartan—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000602	0.00131	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000601	0.00131	CcSEcCtD
Eprosartan—CYP2C9—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000599	0.012	CbGpPWpGaD
Eprosartan—Pain—Formoterol—chronic obstructive pulmonary disease	0.000597	0.0013	CcSEcCtD
Eprosartan—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000597	0.0013	CcSEcCtD
Eprosartan—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000597	0.0013	CcSEcCtD
Eprosartan—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000597	0.0013	CcSEcCtD
Eprosartan—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000596	0.0013	CcSEcCtD
Eprosartan—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000592	0.00129	CcSEcCtD
Eprosartan—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.00059	0.00128	CcSEcCtD
Eprosartan—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000588	0.00128	CcSEcCtD
Eprosartan—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000586	0.00128	CcSEcCtD
Eprosartan—Pain—Montelukast—chronic obstructive pulmonary disease	0.000585	0.00127	CcSEcCtD
Eprosartan—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000583	0.00127	CcSEcCtD
Eprosartan—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.000581	0.00126	CcSEcCtD
Eprosartan—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000581	0.00126	CcSEcCtD
Eprosartan—Purpura—Prednisone—chronic obstructive pulmonary disease	0.00058	0.00126	CcSEcCtD
Eprosartan—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000579	0.00126	CcSEcCtD
Eprosartan—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000578	0.00126	CcSEcCtD
Eprosartan—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.000576	0.00125	CcSEcCtD
Eprosartan—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000576	0.00125	CcSEcCtD
Eprosartan—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000576	0.00125	CcSEcCtD
Eprosartan—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000575	0.00125	CcSEcCtD
Eprosartan—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000573	0.00125	CcSEcCtD
Eprosartan—Cardiac failure—Prednisone—chronic obstructive pulmonary disease	0.000573	0.00125	CcSEcCtD
Eprosartan—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000572	0.00124	CcSEcCtD
Eprosartan—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000571	0.00124	CcSEcCtD
Eprosartan—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000571	0.00124	CcSEcCtD
Eprosartan—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000569	0.00124	CcSEcCtD
Eprosartan—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000564	0.00123	CcSEcCtD
Eprosartan—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000564	0.00123	CcSEcCtD
Eprosartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000561	0.0112	CbGpPWpGaD
Eprosartan—AGTR1—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.000559	0.0112	CbGpPWpGaD
Eprosartan—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000559	0.00122	CcSEcCtD
Eprosartan—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	0.000559	0.00122	CcSEcCtD
Eprosartan—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000555	0.00121	CcSEcCtD
Eprosartan—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000555	0.00121	CcSEcCtD
Eprosartan—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000552	0.0012	CcSEcCtD
Eprosartan—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000552	0.0012	CcSEcCtD
Eprosartan—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000552	0.0012	CcSEcCtD
Eprosartan—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000552	0.0012	CcSEcCtD
Eprosartan—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.00055	0.0012	CcSEcCtD
Eprosartan—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000546	0.00119	CcSEcCtD
Eprosartan—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000545	0.00119	CcSEcCtD
Eprosartan—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000545	0.00119	CcSEcCtD
Eprosartan—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000543	0.00118	CcSEcCtD
Eprosartan—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000543	0.00118	CcSEcCtD
Eprosartan—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000542	0.00118	CcSEcCtD
Eprosartan—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.000542	0.00118	CcSEcCtD
Eprosartan—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000541	0.00118	CcSEcCtD
Eprosartan—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000541	0.00118	CcSEcCtD
Eprosartan—Face oedema—Prednisone—chronic obstructive pulmonary disease	0.00054	0.00117	CcSEcCtD
Eprosartan—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000539	0.00117	CcSEcCtD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000535	0.0107	CbGpPWpGaD
Eprosartan—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000524	0.00114	CcSEcCtD
Eprosartan—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000521	0.00113	CcSEcCtD
Eprosartan—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000521	0.00113	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—SERPINA1—chronic obstructive pulmonary disease	0.000518	0.0104	CbGpPWpGaD
Eprosartan—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000515	0.00112	CcSEcCtD
Eprosartan—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000515	0.00112	CcSEcCtD
Eprosartan—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000514	0.00112	CcSEcCtD
Eprosartan—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000513	0.00112	CcSEcCtD
Eprosartan—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.000509	0.00111	CcSEcCtD
Eprosartan—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000504	0.0011	CcSEcCtD
Eprosartan—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000501	0.00109	CcSEcCtD
Eprosartan—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000501	0.00109	CcSEcCtD
Eprosartan—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000494	0.00107	CcSEcCtD
Eprosartan—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000494	0.00107	CcSEcCtD
Eprosartan—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	0.000493	0.00107	CcSEcCtD
Eprosartan—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000493	0.00107	CcSEcCtD
Eprosartan—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000491	0.00107	CcSEcCtD
Eprosartan—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000486	0.00106	CcSEcCtD
Eprosartan—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000484	0.00105	CcSEcCtD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000479	0.0096	CbGpPWpGaD
Eprosartan—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000478	0.00104	CcSEcCtD
Eprosartan—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000478	0.00104	CcSEcCtD
Eprosartan—ABCC2—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000476	0.00954	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—GCLC—chronic obstructive pulmonary disease	0.000474	0.00948	CbGpPWpGaD
Eprosartan—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000473	0.00103	CcSEcCtD
Eprosartan—Sweating increased—Prednisone—chronic obstructive pulmonary disease	0.000471	0.00102	CcSEcCtD
Eprosartan—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000468	0.00102	CcSEcCtD
Eprosartan—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000467	0.00101	CcSEcCtD
Eprosartan—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000462	0.001	CcSEcCtD
Eprosartan—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000462	0.001	CcSEcCtD
Eprosartan—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000452	0.000984	CcSEcCtD
Eprosartan—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000451	0.000982	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	0.000449	0.00899	CbGpPWpGaD
Eprosartan—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000444	0.000966	CcSEcCtD
Eprosartan—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000444	0.000966	CcSEcCtD
Eprosartan—Rash—Formoterol—chronic obstructive pulmonary disease	0.00044	0.000958	CcSEcCtD
Eprosartan—Rash—Arformoterol—chronic obstructive pulmonary disease	0.00044	0.000958	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—SLC6A4—chronic obstructive pulmonary disease	0.00044	0.00882	CbGpPWpGaD
Eprosartan—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.00044	0.000957	CcSEcCtD
Eprosartan—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.00044	0.000957	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—chronic obstructive pulmonary disease	0.000438	0.00878	CbGpPWpGaD
Eprosartan—Headache—Formoterol—chronic obstructive pulmonary disease	0.000438	0.000952	CcSEcCtD
Eprosartan—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000438	0.000952	CcSEcCtD
Eprosartan—AGTR1—Allograft Rejection—CXCL8—chronic obstructive pulmonary disease	0.000437	0.00875	CbGpPWpGaD
Eprosartan—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000436	0.000949	CcSEcCtD
Eprosartan—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000436	0.000948	CcSEcCtD
Eprosartan—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000435	0.000946	CcSEcCtD
Eprosartan—Rash—Montelukast—chronic obstructive pulmonary disease	0.000431	0.000938	CcSEcCtD
Eprosartan—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000431	0.000937	CcSEcCtD
Eprosartan—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.00043	0.000935	CcSEcCtD
Eprosartan—Depression—Prednisone—chronic obstructive pulmonary disease	0.00043	0.000935	CcSEcCtD
Eprosartan—Headache—Montelukast—chronic obstructive pulmonary disease	0.000429	0.000932	CcSEcCtD
Eprosartan—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000423	0.000921	CcSEcCtD
Eprosartan—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	0.000422	0.000919	CcSEcCtD
Eprosartan—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000419	0.000912	CcSEcCtD
Eprosartan—AGTR1—Allograft Rejection—IL1B—chronic obstructive pulmonary disease	0.000419	0.00839	CbGpPWpGaD
Eprosartan—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000418	0.000909	CcSEcCtD
Eprosartan—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000416	0.000906	CcSEcCtD
Eprosartan—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000416	0.000905	CcSEcCtD
Eprosartan—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000416	0.000904	CcSEcCtD
Eprosartan—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000415	0.000904	CcSEcCtD
Eprosartan—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000415	0.000902	CcSEcCtD
Eprosartan—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000415	0.000902	CcSEcCtD
Eprosartan—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000413	0.000899	CcSEcCtD
Eprosartan—CYP2C9—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000412	0.00825	CbGpPWpGaD
Eprosartan—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000407	0.000886	CcSEcCtD
Eprosartan—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000406	0.000884	CcSEcCtD
Eprosartan—AGTR1—G alpha (q) signalling events—EDN1—chronic obstructive pulmonary disease	0.000406	0.00813	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—EDN1—chronic obstructive pulmonary disease	0.000401	0.00802	CbGpPWpGaD
Eprosartan—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.000394	0.000857	CcSEcCtD
Eprosartan—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000392	0.000852	CcSEcCtD
Eprosartan—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.00039	0.000848	CcSEcCtD
Eprosartan—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000372	0.00081	CcSEcCtD
Eprosartan—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000369	0.000803	CcSEcCtD
Eprosartan—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000366	0.000795	CcSEcCtD
Eprosartan—AGTR1—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000365	0.00731	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000364	0.0073	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic obstructive pulmonary disease	0.000363	0.00727	CbGpPWpGaD
Eprosartan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000356	0.00713	CbGpPWpGaD
Eprosartan—AGTR1—G alpha (q) signalling events—HTR2A—chronic obstructive pulmonary disease	0.000355	0.00711	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—VEGFA—chronic obstructive pulmonary disease	0.000355	0.00711	CbGpPWpGaD
Eprosartan—CYP2C9—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000351	0.00704	CbGpPWpGaD
Eprosartan—AGTR1—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000351	0.00703	CbGpPWpGaD
Eprosartan—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000342	0.000744	CcSEcCtD
Eprosartan—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.00034	0.000739	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	0.000332	0.00665	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	0.000327	0.00656	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	0.000326	0.00652	CbGpPWpGaD
Eprosartan—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000323	0.000704	CcSEcCtD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—chronic obstructive pulmonary disease	0.000317	0.00636	CbGpPWpGaD
Eprosartan—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000312	0.00068	CcSEcCtD
Eprosartan—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000312	0.000678	CcSEcCtD
Eprosartan—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000308	0.000669	CcSEcCtD
Eprosartan—ABCC2—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	0.000305	0.00611	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—TNF—chronic obstructive pulmonary disease	0.000304	0.00609	CbGpPWpGaD
Eprosartan—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000304	0.000661	CcSEcCtD
Eprosartan—Vertigo—Prednisone—chronic obstructive pulmonary disease	0.000303	0.000658	CcSEcCtD
Eprosartan—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000302	0.000657	CcSEcCtD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000301	0.00602	CbGpPWpGaD
Eprosartan—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.0003	0.000654	CcSEcCtD
Eprosartan—CYP2C9—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000299	0.006	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000299	0.00599	CbGpPWpGaD
Eprosartan—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000296	0.000644	CcSEcCtD
Eprosartan—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000289	0.00578	CbGpPWpGaD
Eprosartan—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000287	0.000624	CcSEcCtD
Eprosartan—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000287	0.000624	CcSEcCtD
Eprosartan—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000286	0.000622	CcSEcCtD
Eprosartan—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000283	0.000616	CcSEcCtD
Eprosartan—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000279	0.000606	CcSEcCtD
Eprosartan—AGTR1—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000274	0.00549	CbGpPWpGaD
Eprosartan—Shock—Prednisone—chronic obstructive pulmonary disease	0.00027	0.000588	CcSEcCtD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000269	0.00538	CbGpPWpGaD
Eprosartan—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.000268	0.000584	CcSEcCtD
Eprosartan—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000266	0.000578	CcSEcCtD
Eprosartan—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.000262	0.00057	CcSEcCtD
Eprosartan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000259	0.00518	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000256	0.00512	CbGpPWpGaD
Eprosartan—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000255	0.00511	CbGpPWpGaD
Eprosartan—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.00025	0.000545	CcSEcCtD
Eprosartan—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.00025	0.000544	CcSEcCtD
Eprosartan—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000249	0.000541	CcSEcCtD
Eprosartan—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	0.000247	0.000537	CcSEcCtD
Eprosartan—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000242	0.000526	CcSEcCtD
Eprosartan—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000239	0.00052	CcSEcCtD
Eprosartan—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000238	0.000519	CcSEcCtD
Eprosartan—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000238	0.000518	CcSEcCtD
Eprosartan—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000237	0.000515	CcSEcCtD
Eprosartan—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000237	0.000515	CcSEcCtD
Eprosartan—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000235	0.000511	CcSEcCtD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000235	0.00471	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000232	0.00465	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000229	0.00459	CbGpPWpGaD
Eprosartan—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000226	0.000493	CcSEcCtD
Eprosartan—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000225	0.000489	CcSEcCtD
Eprosartan—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000225	0.000489	CcSEcCtD
Eprosartan—Urticaria—Prednisone—chronic obstructive pulmonary disease	0.000218	0.000475	CcSEcCtD
Eprosartan—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000217	0.000473	CcSEcCtD
Eprosartan—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.000217	0.000473	CcSEcCtD
Eprosartan—AGTR1—Peptide ligand-binding receptors—CXCL8—chronic obstructive pulmonary disease	0.000216	0.00434	CbGpPWpGaD
Eprosartan—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.00021	0.0042	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000206	0.00413	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000205	0.0041	CbGpPWpGaD
Eprosartan—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000203	0.000441	CcSEcCtD
Eprosartan—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000197	0.000429	CcSEcCtD
Eprosartan—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000194	0.000423	CcSEcCtD
Eprosartan—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000188	0.000409	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000187	0.00375	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000185	0.0037	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000182	0.00365	CbGpPWpGaD
Eprosartan—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000182	0.000395	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000181	0.00363	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.000179	0.00358	CbGpPWpGaD
Eprosartan—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000175	0.00038	CcSEcCtD
Eprosartan—Rash—Prednisone—chronic obstructive pulmonary disease	0.000173	0.000377	CcSEcCtD
Eprosartan—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000173	0.000377	CcSEcCtD
Eprosartan—Headache—Prednisone—chronic obstructive pulmonary disease	0.000172	0.000375	CcSEcCtD
Eprosartan—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000163	0.000355	CcSEcCtD
Eprosartan—CYP2C9—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000153	0.00307	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000151	0.00303	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	0.000145	0.00291	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	0.000143	0.00287	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.000137	0.00275	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	0.00013	0.0026	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	0.000129	0.00259	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000128	0.00256	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	0.000126	0.00253	CbGpPWpGaD
Eprosartan—ABCC2—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	0.000124	0.00249	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000118	0.00235	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	0.000117	0.00235	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	0.000116	0.00232	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	0.000116	0.00232	CbGpPWpGaD
Eprosartan—CYP2C9—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000111	0.00223	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	0.000111	0.00222	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	0.000111	0.00221	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	0.00011	0.00221	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	0.00011	0.0022	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	0.000105	0.0021	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	0.000105	0.0021	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	0.000101	0.00203	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	9.19e-05	0.00184	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—APIP—chronic obstructive pulmonary disease	8.97e-05	0.0018	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	8.09e-05	0.00162	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—KL—chronic obstructive pulmonary disease	7.52e-05	0.00151	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	6.94e-05	0.00139	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	6.39e-05	0.00128	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	6.3e-05	0.00126	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	6.25e-05	0.00125	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	6.2e-05	0.00124	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	5.94e-05	0.00119	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	5.89e-05	0.00118	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	5.78e-05	0.00116	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	5.67e-05	0.00114	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	5.64e-05	0.00113	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	5.43e-05	0.00109	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	5.37e-05	0.00108	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	5.04e-05	0.00101	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	4.28e-05	0.000857	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	4.15e-05	0.000831	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.96e-05	0.000793	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.78e-05	0.000757	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.35e-05	0.000671	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.19e-05	0.000638	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.16e-05	0.000632	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	3.12e-05	0.000625	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.03e-05	0.000607	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	2.91e-05	0.000583	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	2.85e-05	0.00057	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.72e-05	0.000545	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.62e-05	0.000525	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.5e-05	0.0005	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.45e-05	0.000491	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.19e-05	0.000438	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.16e-05	0.000432	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.06e-05	0.000412	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.01e-05	0.000403	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.91e-05	0.000382	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.88e-05	0.000377	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	1.3e-05	0.000259	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	1.24e-05	0.000248	CbGpPWpGaD
